-
OncoTargets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Role of bendamustine in the treatment of chronic lymphocytic leukemia
Review
(3260) Views (1234) Full article downloads
Authors: Saad Jamshed, Bruce D Cheson
Published Date March 2009
Volume 2009:2 Pages 43 - 49
DOI: http://dx.doi.org/10.2147/OTT.S3913
Saad Jamshed, Bruce D Cheson
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA
Abstract: Major advances in the management of patients with chronic lymphocytic leukemia (CLL) include an enhanced ability to make an accurate diagnosis and define clinically meaningful prognostic groups, while improving outcome through more effective therapeutic regimens and supportive care. Nevertheless, CLL remains an incurable disorder and new, active agents are needed. Bendamustine, a unique cytotoxic agent with structural similarities to both alkylating agents and antimetabolites, was recently approved by the US Food and Drug Administration for treatment of CLL and rituximab-refractory indolent non-Hodgkin’s lymphoma. In a randomized trial, bendamustine was superior to chlorambucil, with comparable toxicity. Combinations with other active agents including rituximab and lenalidomide are in development. Nevertheless, numerous questions concerning the ideal use of this agent remain to be addressed, including the optimal dose and schedule and mechanisms of resistance. The availability of bendamustine provides another effective treatment option for patients with lymphoproliferative disorders. Rational development of combination regimens will improve the outlook for patients with CLL.
Keywords: bendamustine, chemotherapy, chronic lymphocytic leukemia
Readers of this article also read:
Multiple roles and therapeutic implications of Akt signaling in cancer
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
Bendamustine in the treatment of non-Hodgkin’s lymphomas
Health literacy and health seeking behavior among older men in a middle-income nation
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Zinc oxide nanoparticles as selective killers of proliferating cells
Differences in maintenance of mean blood glucose (BG) and their association with response to “recognizing hunger”
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Intranet access to all Dove journals
If you would like your institutional intranet to have access to the Dove Medical Press journals please contact me.
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Topotecan in the treatment of relapsed small cell lung cancer
- Role of trabectedin in the treatment of soft tissue sarcoma




